Ebselen abolishes vascular dysfunction in influenza A virus-induced exacerbations of cigarette smoke-induced lung inflammation in mice.


Journal

Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731

Informations de publication

Date de publication:
29 04 2022
Historique:
received: 16 11 2021
revised: 16 03 2022
accepted: 28 03 2022
pubmed: 29 3 2022
medline: 23 4 2022
entrez: 28 3 2022
Statut: ppublish

Résumé

People with chronic obstructive pulmonary disease (COPD) are susceptible to respiratory infections which exacerbate pulmonary and/or cardiovascular complications, increasing their likelihood of death. The mechanisms driving these complications remain unknown but increased oxidative stress has been implicated. Here we investigated whether influenza A virus (IAV) infection, following chronic cigarette smoke (CS) exposure, worsens vascular function and if so, whether the antioxidant ebselen alleviates this vascular dysfunction. Male BALB/c mice were exposed to either room air or CS for 8 weeks followed by inoculation with IAV (Mem71, 1 × 104.5 pfu). Mice were treated with ebselen (10 mg/kg) or vehicle (5% w/v CM-cellulose in water) daily. Mice were culled 3- and 10-days post-infection, and their lungs lavaged to assess inflammation. The thoracic aorta was excised to investigate endothelial and smooth muscle dilator responses, expression of key vasodilatory and oxidative stress modulators, infiltrating immune cells and vascular remodelling. CS increased lung inflammation and caused significant vascular endothelial dysfunction, which was worsened by IAV infection. CS-driven increases in vascular oxidative stress, aortic wall remodelling and suppression of endothelial nitric oxide synthase (eNOS) were not affected by IAV infection. CS and IAV infection significantly enhanced T cell recruitment into the aortic wall. Ebselen abolished the exaggerated lung inflammation, vascular dysfunction and increased T cell infiltration in CS and IAV-infected mice. Our findings showed that ebselen treatment abolished vascular dysfunction in IAV-induced exacerbations of CS-induced lung inflammation indicating it may have potential for the treatment of cardiovascular comorbidities seen in acute exacerbations of COPD (AECOPD).

Identifiants

pubmed: 35343564
pii: 231085
doi: 10.1042/CS20211090
pmc: PMC9069468
doi:

Substances chimiques

Azoles 0
Isoindoles 0
Organoselenium Compounds 0
ebselen 40X2P7DPGH

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

537-555

Informations de copyright

© 2022 The Author(s).

Références

Cell Rep Med. 2020 Apr 21;1(1):
pubmed: 32483557
Int J Surg. 2020 Dec;84:53-56
pubmed: 33120196
Life Sci. 2015 Aug 1;134:9-15
pubmed: 26006036
J Allergy Clin Immunol. 2016 Jul;138(1):16-27
pubmed: 27373322
Am J Physiol Lung Cell Mol Physiol. 2010 Sep;299(3):L425-33
pubmed: 20511341
Pharmacol Ther. 2015 Nov;155:60-79
pubmed: 26297673
Thorax. 2012 Dec;67(12):1067-74
pubmed: 22843558
Inflammation. 2013 Dec;36(6):1485-93
pubmed: 23872721
Immunol Allergy Clin North Am. 2013 Feb;33(1):95-115
pubmed: 23337067
Clin Sci (Lond). 2016 Jul 1;130(13):1039-50
pubmed: 27215677
Hypertension. 2001 Aug;38(2):274-9
pubmed: 11509489
Nat Rev Drug Discov. 2011 Jun;10(6):453-71
pubmed: 21629295
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677
Proc Am Thorac Soc. 2005;2(1):8-11
pubmed: 16113462
J Virol. 2004 Oct;78(20):11246-57
pubmed: 15452243
J Med Virol. 2010 Jan;82(1):1-7
pubmed: 19950247
Br J Pharmacol. 2021 Apr;178(8):1805-1818
pubmed: 33523477
Respir Res. 2008 Jul 15;9:53
pubmed: 18627612
Mol Pharmacol. 2014 Dec;86(6):747-59
pubmed: 25301784
Clin Sci (Lond). 2016 Aug 1;130(15):1363-74
pubmed: 27190136
Eur Respir J. 2017 Nov 22;50(5):
pubmed: 29167301
Eur Respir J. 2000 Mar;15(3):579-81
pubmed: 10759456
Thorax. 1996 Mar;51(3):267-71
pubmed: 8779129
J Mol Cell Cardiol. 2006 Aug;41(2):275-84
pubmed: 16806264
Front Cardiovasc Med. 2019 Jun 25;6:79
pubmed: 31294030
Thorax. 2008 Apr;63(4):301-5
pubmed: 17951276
N Engl J Med. 2018 May 03;378(18):1671-1680
pubmed: 29668352
Int J Chron Obstruct Pulmon Dis. 2016 Jul 13;11:1579-86
pubmed: 27471380
J Clin Invest. 2012 Jan;122(1):70-9
pubmed: 22201681
Int J Vasc Med. 2012;2012:918267
pubmed: 22611498
Am J Respir Crit Care Med. 2016 Jul 1;194(1):38-47
pubmed: 26771278
Sci Rep. 2016 Feb 15;6:20983
pubmed: 26877172
Am J Hypertens. 2009 Jun;22(6):586-92
pubmed: 19300425
J Theor Biol. 2015 Jun 7;374:83-93
pubmed: 25843213
J Immunol. 2002 Jul 15;169(2):974-82
pubmed: 12097404
Chest. 2013 May;143(5):1444-1454
pubmed: 23648908
Am J Respir Cell Mol Biol. 2013 Jan;48(1):17-26
pubmed: 23002098
Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L931-45
pubmed: 16361358
Basic Res Cardiol. 2011 Sep;106(5):735-47
pubmed: 21598086
Eur Respir Rev. 2018 Oct 3;27(149):
pubmed: 30282634
J Clin Invest. 1998 Feb 1;101(3):643-9
pubmed: 9449698
Curr Pharm Des. 2014;20(22):3579-94
pubmed: 24180381
Am J Respir Cell Mol Biol. 2020 Feb;62(2):217-230
pubmed: 31461300
Pulm Circ. 2018 Jan-Mar;8(1):2045894018758528
pubmed: 29468936
J Neurochem. 2008 Oct;107(1):241-52
pubmed: 18691391
Clin Sci (Lond). 2014 Feb;126(4):253-65
pubmed: 24144354
Antioxidants (Basel). 2018 Oct 19;7(10):
pubmed: 30347720
COPD. 2018 Oct;15(5):496-502
pubmed: 30475645
Hypertension. 2007 Jul;50(1):212-8
pubmed: 17515450
PLoS Pathog. 2011 Feb 03;7(2):e1001271
pubmed: 21304882
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2114-21
pubmed: 16037565
Microbes Infect. 2012 Jan;14(1):50-8
pubmed: 21920449
PLoS One. 2010 Jan 14;5(1):e8718
pubmed: 20090932
Thorax. 2017 Aug;72(8):686-693
pubmed: 28235886
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):24964-24973
pubmed: 32958663
Curr Pharm Des. 2014;20(22):3595-606
pubmed: 24180386
Antioxid Redox Signal. 2010 Sep 1;13(5):575-87
pubmed: 20367278
Eur Heart J Acute Cardiovasc Care. 2012 Apr;1(1):60-74
pubmed: 24062891
J Exp Med. 2007 Oct 1;204(10):2449-60
pubmed: 17875676
Int J Chron Obstruct Pulmon Dis. 2014 Oct 17;9:1207-24
pubmed: 25378921
Front Pharmacol. 2020 Jan 21;10:1568
pubmed: 32038245
Clin Sci (Lond). 2019 Apr 12;133(7):885-904
pubmed: 30979844
Glob Health Epidemiol Genom. 2018 Apr 6;3:e4
pubmed: 29868229

Auteurs

Kurt Brassington (K)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Stanley M H Chan (SMH)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Simone N De Luca (SN)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Aleksandar Dobric (A)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Suleman A Almerdasi (SA)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Kevin Mou (K)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Huei Jiunn Seow (HJ)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Osezua Oseghale (O)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Steven Bozinovski (S)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Stavros Selemidis (S)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Ross Vlahos (R)

School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083 Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH